The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”

A phase III study has demonstrated that 6-month pasireotide treatment induced disease control with good safety in 15–26% of patients with Cushing’s disease (CD). The aim of the current study was to evaluate the 6-month efficacy and safety of pasireotide treatment according to the real-world evidence...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Endocrine
Main Authors: Pivonello, Rosario, Arnaldi, Giorgio, Scaroni, Carla, Giordano, Carla, Cannavò, Salvo, Iacuaniello, Davide, Trementino, Laura, Zilio, Marialuisa, Guarnotta, Valentina, Albani, Adriana, Cozzolino, Alessia, Michetti, Grazia, Boscaro, Marco, Colao, Annamaria
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6551343/
https://ncbi.nlm.nih.gov/pubmed/30968338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12020-018-1818-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados